JP2024544625A - がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン - Google Patents

がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン Download PDF

Info

Publication number
JP2024544625A
JP2024544625A JP2024532155A JP2024532155A JP2024544625A JP 2024544625 A JP2024544625 A JP 2024544625A JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024532155 A JP2024532155 A JP 2024532155A JP 2024544625 A JP2024544625 A JP 2024544625A
Authority
JP
Japan
Prior art keywords
cancer
alkyl
bid
combination
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544625A5 (cg-RX-API-DMAC10.html
Inventor
アンダース ラース
リ ジェリー
タン リン タン
リー ヴァナーズダル トッド
ウェイ ピン
ヤン ジン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2024544625A publication Critical patent/JP2024544625A/ja
Publication of JP2024544625A5 publication Critical patent/JP2024544625A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024532155A 2021-12-02 2022-12-01 がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン Pending JP2024544625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
US63/285,457 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Publications (2)

Publication Number Publication Date
JP2024544625A true JP2024544625A (ja) 2024-12-03
JP2024544625A5 JP2024544625A5 (cg-RX-API-DMAC10.html) 2025-11-21

Family

ID=84462534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532155A Pending JP2024544625A (ja) 2021-12-02 2022-12-01 がんを処置するためのcdk2阻害剤およびcdk4阻害剤を含む方法および投薬レジメン

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544625A (cg-RX-API-DMAC10.html)
KR (1) KR20240112932A (cg-RX-API-DMAC10.html)
CN (1) CN118647379A (cg-RX-API-DMAC10.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC10.html)
IL (1) IL312980A (cg-RX-API-DMAC10.html)
MX (1) MX2024006747A (cg-RX-API-DMAC10.html)
TW (1) TWI873485B (cg-RX-API-DMAC10.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
AU2026201311A1 (en) 2026-03-12
IL312980A (en) 2024-07-01
MX2024006747A (es) 2024-06-19
US20250041277A1 (en) 2025-02-06
KR20240112932A (ko) 2024-07-19
TW202332431A (zh) 2023-08-16
ZA202404615B (en) 2025-12-17
TWI873485B (zh) 2025-02-21
WO2023100134A1 (en) 2023-06-08
CA3241001A1 (en) 2023-06-08
CN118647379A (zh) 2024-09-13
EP4440575A1 (en) 2024-10-09
AU2022402512A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
KR102325778B1 (ko) HDM2-p53 상호작용 억제제에 대한 용량 및 요법
US20240000783A1 (en) Combination therapy
TW202210076A (zh) 組合療法
JP2019511204A (ja) コパンリシブバイオマーカー
JP2018512403A (ja) 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン類の使用
US20200281923A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
AU2018241944A1 (en) Anticancer combination therapy
TW201217361A (en) Method of treating abnormal cell growth
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
RU2849370C1 (ru) Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака
JP2025512921A (ja) (19r)-5-クロロ-3-エチル-16-フルオロ-10,19-ジメチル-20-オキサ-3,4,10,11,23-ペンタアザペンタシクロ[19.3.1.02,6.08,12.013,18]ペンタコサ-1(24),2(6),4,8,11,13,15,17,21(25),22-デカエン-22-アミンを使用して固形腫瘍の治療する方法
HK40116611A (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
US20240342157A1 (en) Bak activators, pharmaceutical compositions, and uses in treating cancer
HK40096012A (en) Combination therapy
CA2984357C (en) Methods for treating cancer
TW202535366A (zh) 達羅他胺(darolutamide)組合braf及mek抑制劑以用於黑色素瘤之治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251113